retibial myxedema (PTM) is a term used for the dermal deposition of acid mucopolysaccharides (glycosaminoglycans). These acids are mainly composed of hyaluronic acid (HA) and deposit commonly on the lower legs, feet and particularly the shins. 1, 2 This clinical sign is most often associated with Graves disease, occurring in approximately 2-5% of these patients. 1 It is commonly seen in combination with ophthalmopathy. Graves disease consists of four components including hyperthyroidism secondary to diffuse goiter, ophthalmopathy and dermopathy which is usually PTM, and the presence of long acting thyroid stimulator (LATS). 3 It can and very rarely occurs in non-thyrotoxic thyroid states such as hypothyroidism and euthyroid disorders. These disorders present with three of the four components of Graves disease that include ophthalmopathy, dermopathy, and LATS. 4 Pretibial myxedema presents as a nodular or plaquelike appearance of the skin in the pretibial area. It is often bilateral with a predilection for females in their forties and fifties. 4, 6 The dermopathy may also present with hyperpigmentation and/or non-pitting edema that may be caused by the hygroscopic property of HA. 5, 6 The skin also often has a peau d'orange (orange-skin peel) appearance caused by dilated, follicular openings.
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Case Presentation
A 50 year-old African-American female presents with a five year history of nodular plaques involving the pretibial region of the left lower leg. (Fig.1A and B)
The nodules have progressively enlarged causing discomfort secondary to pressure from shoe gear. Her medical history was significant for diffuse goiter diagnosed in 1993 and breast cancer. She was being treated with Ultravate® and Synthroid®. At the time of PTM diagnosis, the patient was non-thyrotoxic and presented with a T-3 of 29 (22-35%), free T-4 (FT4) of 1.2 (0.8-1.8 ng/dL), total T-4 of 8.1 (4.5-12.5 mcg/dL), total free T-4 index of 2.3 (1.4-3.8) and a TSH with reflex to FT4 of 2.93 (0.4-5.5). Physical examination revealed a well circumscribed, multi-nodular, pretibial plaque located on her left lower leg. Additional nodules were present on the dorsum of her left foot over the area of the cuboid and proximal to the first metatarsophalangeal joint.
Histopathology
A 4 x 4 x 3 mm punch biopsy revealed hyperkeratosis, epidermal hyperplasia and edema located throughout the papillary dermis. This stained positive for mucin with Alcian blue. Hematoxylin and eosin stain shows mucin accumulation causing separation and fraying of collagen fibrils. (Figs.2A and B) 
Discussion
Pretibial myxedema is most accurately diagnosed with a skin biopsy. Characteristics include a hyperkeratotic epidermis and a dermis that contains increased amounts of mucin or glycosaminoglycans (GAG), mainly hyaluronate. These substances are produced by dermal fibroblasts and their synthesis is regulated by thyroid and glucocorticoid hormones. The hyaluronic acid accumulates extensively in the upper dermis. Stellate or spindle-shaped fibroblasts may show an increase in number along the middle to lower dermis. Separation and fraying of collagen fibrils is seen secondary to the large accumulation of GAG. 4, 5 The pathogenesis of PTM is still unknown. The presence of LATS is thought to play a role in the development, but not the severity of PTM. LATS is an immunoglobulin of the IgG family that represents an autoantibody to the TSH receptor. It is present in 95 to 100% of patients with PTM.
It is believed that this antibody with other anti-thyroid stimulator hormone-receptor antibodies can crossreact with the pretibial dermis to stimulate collagen synthesis by fibroblasts. However, a cofactor may be needed for this cross-reaction to occur as it has not been shown to directly affect fibroblasts from pretibial tissue in vitro. 5, 7 Serum-derived-hyaluronan-associated protein (SHAP) is also thought to play a role in the development of pretibial myxedema. SHAP has been characterized as a mediator between the cell surface and HA, and appears to be involved in both HA-cell interactions and HA metabolism. It has been isolated as an HA binding protein found on the surface of fibroblasts particularly in the middle to lower dermis indicating that HA accumulation progresses from the upper to the lower dermis. Therefore, the interaction between fibroblasts and SHAP may also result in the deposition of excess HA leading to cutaneous changes seen in pretibial myxedema.
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Summary
Although this patient was lost to follow-up and received no further treatment, the majority of cases do not require therapy with 50% of mild cases achieving complete remission after several years. Treatment primarily consists of palliative care with corticosteroids applied under occlusion. 7 Other treatment methods are being studied in more severe cases. The use of intra-lesional octreotide, an antagonist to insulin-like growth factor 1 (IGF-1), suggests down regulation of hyaluronic acid production by lesional fibroblasts. 8 The immunologic role suspected in the pathogenesis and immunomodulation with high dose intravenous immunoglobulin therapy is also being studied. 
